Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 by veteran biotech entrepreneurs David F. Hale and Jeffrey Raser to focus on central nervous system (CNS) diseases and disorders.
The Company’s first drug candidate is tolperisone, which has been shown to be an effective treatment for muscle spasms and spasticity and is commercialized in markets outside of the United States. Clinical studies and commercial usage have shown that tolperisone is safe and efficacious, and that the drug is non-sedating.
Neurana has been financed to date by private investors, including MagnaSci Ventures, a Houston based healthcare fund focused on investing in early stage life science companies with exceptional science and entrepreneurs.